This is the standing evidence sheet for Moderna (MRNA): the yardsticks BullScope computes from official SEC filings and market prices. It refreshes whenever a new edition of our research is published, and it is impersonal by design, every reader sees the same page. Nothing here is investment advice; it is the evidence, organized.
The price tag: what buyers pay per dollar of profit
As the filed record below shows, Moderna has reported negative GAAP EPS in each of FY2023, FY2024, and FY2025, making a conventional trailing price-to-earnings ratio undefined on a GAAP basis. If and when the company returns to positive earnings, the price-to-earnings multiple implied by the current share price can be compared against the historical median of 4.4 recorded during the profitable FY2021–FY2022 period.
The tape: what the stock itself has done
- Last price: $254.19 (end-of-day market data as of the edition date · methodology) · 2% below its 52-week high
- Past 6-month and 12-month return figures are not shown here pending source verification against the named market-data provider; see the edition date and methodology page for data sourcing details.
- Day-to-day temperament: jumpy (annualized volatility 194%)
The filed record: straight from the annual reports
| Fiscal year | Revenue | Growth | Operating margin | EPS |
|---|---|---|---|---|
| FY2021 | $18.5B | , | 72.0% | $28.29 |
| FY2022 | $19.3B | +4.3% | 48.9% | $20.12 |
| FY2023 | $6.8B | -64.4% | -61.9% | $-12.33 |
| FY2024 | $3.2B | -52.7% | -121.9% | $-9.28 |
| FY2025 | $1.9B | -39.9% | -158.1% | $-7.26 |
The road ahead: filed results vs published expectations
| FY2023A | FY2024A | FY2025A | FY2026E | FY2027E | FY2028E | |
|---|---|---|---|---|---|---|
| Net sales ($B) | 6.8 | 3.2 | 1.9 | 2.1 to 2.5 | 1.5 to 3.5 | 1.6 to 5.2 |
| Net sales growth (%) | -64.2 | -52.9 | -40.6 | 10 | -29 | 6 |
| Operating margin (%) | -61.8 | -121.9 | -163.2 | -145 to -110 | -175 to -60 | -135 to -85 |
| Diluted EPS ($) | -12.33 | -9.28 | -7.26 | -9.50 to -6.50 | -12.00 to -2.50 | -11.00 to -7.50 |
Columns marked A are actual filed results; E columns are the published consensus ranges the current price is being weighed against.
The four gauges: from the latest edition
BullScope coverage of Moderna
- Moderna Brings Back Operations Chief as Oncology Push Demands Manufacturing Scale
- Moderna at 28 Times Sales: One Trial Result Is Doing a Lot of Work
- Moderna raises $2.6 billion in zero-coupon convertibles as revenue collapses, betting oncology turnaround
Read the full report on Moderna in the BullScope Terminal → It opens with this company loaded.
Edition date: 2026-11-09. This page updates when a new edition is published. Sources: SEC EDGAR filings, Nasdaq prices; computed by BullScope’s published methodology.









